Company intelligence / Profile preview
Takeda
Osaka City, Osaka Prefecture, Japantakeda.com ↗
- Ownership
- Public · TAK
- Employees
- ~49000
- Development stage
- Other
01
Overview
Takeda has a robust late-stage pipeline with six key assets in Phase 3 or registration stages targeting CNS disorders, autoimmune diseases, hematologic malignancies, and rare genetic conditions. Its lead product Entyvio faces biosimilar competition by the early next decade. The new pipeline could collectively generate $10–20B in peak sales if approved. Recent clinical results include positive data from pivotal trials in narcolepsy and polycythemia vera.[6]
- Therapeutic areas
- GastroenterologyOncologyImmunologyDermatologyHematologyNeurology
- Modalities
- Small molecules[10]Antibody-drug conjugates (ADCs)[10]Complex biologics[10]Gamma delta T cell therapies[10]Peptides[6]
- Industry
- Pharma
02
Drug pipeline
384 assets383 more assets in the full pipeline.
03
Financials
- Market cap
- $67.2B
- Total revenue
- $30.2B
- Enterprise value
- $93.3B
Beyond the preview
Go deeper on Takeda.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Takeda.